Nautilus Biotechnology, Inc.
NASDAQ:NAUTBiotechnology
+$0.05 today
- Market cap
- $309.51M
- Beta
- 0.75
- P/E (TTM)
- -4.9
- EPS (TTM)
- -$0.45
Volume 4.55M
Average 0.40M
NAUT Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Nautilus Biotechnology, Inc.NASDAQ: NAUT
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity falls 25.7% from a year ago
Total equity stood at $144.42M at the end of Q1 FY2026, down 25.7% from a year earlier and down 8.0% from the prior quarter. Over 3 fiscal years it compounded at -20.7% a year.
Context
- Total equity amounted to 81.2% of total assets at the end of Q1 FY2026, down 4.2 pp from a year earlier.
- Total equity increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps falling in the next quarterly balance sheet after a -25.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 156.97M USD
- Year-over-year change
- -24.8%
- 4-year CAGR
- -18.9%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 156.97M | -24.8% |
| FY2024 | 2024-12-31 | 208.73M | -21.3% |
| FY2023 | 2023-12-31 | 265.35M | -15.7% |
| FY2022 | 2022-12-31 | 314.92M | -13.4% |
| FY2021 | 2021-12-31 | 363.58M | — |
Total Equity vs competitors
How NAUT compares with its peers on the latest reported figures
- NAUT's Mar 2026 total equity of $144.42M is the 5th highest of the 11 companies compared; the peer median is $111.39M.
- Its year-over-year change of -25.7% is the 8th highest of 11, against a peer median of -14.6%.
- Total equity amounts to 81.2% of total assets for NAUT, versus a peer median of 78.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $206.52B | +493455.8% | +25.8% | 96.1% | |
ZURAZura Bio Limited | Mar 2026 | $216.9M | +43.3% | — | 94.9% |
| Mar 2026 | $198.61M | +632.0% | +35.7% | 84.3% | |
| Mar 2026 | $191.36M | -18.1% | -7.5% | 78.0% | |
| Mar 2026 | $144.42M | -25.7% | -20.7% | 81.2% | |
| Mar 2026 | $116.59M | +24.6% | -41.4% | 37.0% | |
| Mar 2026 | $106.19M | -11.1% | -20.3% | 78.6% | |
SGMTSagimet Biosciences Inc. | Mar 2026 | $102.46M | -26.3% | — | 95.1% |
| Mar 2026 | $31.27M | -69.7% | -30.8% | 48.6% | |
| Mar 2026 | $11.62M | -67.7% | -70.2% | 10.5% | |
| Mar 2026 | -$76.41M | -23.9% | — | 34.4% | |
| Peer median (excluding NAUT) | $111.39M | -14.6% | -20.3% | 78.3% | |
Competitors are the stored peer set for NAUT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 185.62M | 114.52M | 19.4M | 27.65M | 12.39M |
| Short-term Investments | 160.11M | 69.95M | 154.02M | 102.25M | 91.02M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 3.42M | 2.93M | 2.56M |
| Total Current Assets | 349.22M | 187.21M | 176.84M | 132.83M | 105.96M |
| Property, Plant & Equipment (Net) | 31.86M | 32.57M | 36.9M | 32.33M | 31.23M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 16.37M | 129.17M | 90.65M | 76.41M | 52.74M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 997K | 1.11M | 1.18M | 1.18M | 1.18M |
| Total Non-current Assets | 49.23M | 162.84M | 128.73M | 109.92M | 85.15M |
| Total Assets | 398.45M | 350.05M | 305.57M | 242.74M | 191.11M |
| Account Payables | 1.72M | 1.27M | 1.64M | 987K | 943K |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 388K | 438K | 2.97M | 1.86M | 2.7M |
| Total Current Liabilities | 5.81M | 6.79M | 9.12M | 7.63M | 7.95M |
| Long-term Debt | 0 | 0 | 0 | 0 | 26.19M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 29.06M | 28.34M | 31.09M | 26.38M | 26.19M |
| Total Liabilities | 34.87M | 35.13M | 40.21M | 34.01M | 34.14M |
| Common Stock | 12K | 12K | 13K | 13K | 13K |
| Retained Earnings | (80.64M) | (138.56M) | (202.24M) | (273.02M) | (332.02M) |
| Accumulated OCI | (184K) | (1.85M) | (255K) | 57K | 243K |
| Other Stockholders Equity | (0) | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 363.58M | 314.92M | 265.35M | 208.73M | 156.97M |
| Total Debt | 30.03M | 30.33M | 34.63M | 30.48M | 30.02M |
| Net Debt | (155.59M) | (84.2M) | 15.23M | 2.83M | 17.63M |
Nautilus Biotechnology, Inc.
NASDAQ:NAUT
Intrinsic Alpha fair value
Locked
Current Price
$2.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.